All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Request for approval of daratumumab plus pomalidomide and dexamethasone submitted to EMA and FDA
By Claire Baker
On November 12, 2020, regulatory applications were submitted to the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) requesting the approval of subcutaneous daratumumab in combination with pomalidomide and dexamethasone (D-Pd) for the treatment of relapsed or refractory multiple myeloma (RRMM).
Positive topline results from the phase III APOLLO study provided the foundations for the submission. The D-Pd regimen containing the intravenous formulation of daratumumab was approved by the FDA in 2017 for the treatment of patients with RRMM following at least two prior therapies, including lenalidomide and a proteasome inhibitor.
The full results from the APOLLO study will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting on December 6 (abstract #412).
PharmiWeb/Janssen. Janssen submits applications in the EU and U.S. seeking approval of DARZALEX®▼ (daratumumab) subcutaneous formulation in combination with pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma. https://www.pharmiweb.com/press-release/2020-11-13/janssen-submits-applications-in-the-eu-and-us-seeking-approval-of-darzalex-daratumumab-subcutaneous-formulation-in-combination-with-pomalidomide. Accessed Nov 13, 2020. Published Nov 13, 2020.
Your opinion matters
47 votes - 9 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox